Browse Studies — Arctuva

Phase 3

A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2 (MacTel), Including a Randomized Comparative Expansion Cohort

The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501…

Macular Telangiectasia Type 2

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Neurotech PharmaceuticalsNCT06397131

Phase 3

Phase 3 Study of Serine Supplementation to Protect Vision in MacTel

The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional cha…

Macular Telangiectasia Type 2 (MacTel)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

The Lowy Medical Research Institute LimitedNCT07342439

Phase 4

A Phase 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted During a Phase 1, Phase 2, or Phase 3 Clinical Study and to Evaluate NT-501 Implanted in Participants Who Underwent the Sham Procedure in a Phase 3 Clinical Study of Macular Telangiectasia Type 2 (MacTel)

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretc…

Macular Telangiectasia Type 2 (MacTel)

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Neurotech PharmaceuticalsNCT06971939